Because tau aggregation as measured by PET33 and by CSF34 is tightly associated with brain metabolism, the results of our study suggest that plasma p-tau181 can serve as a less invasive and more accessible measure of Alzheimer’s disease-related cerebral metabolic dysfunction. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.